Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity.

ABSTRACT:

Objectives

To evaluate the relationship between radiographic progression and disease activity in subjects with PsA treated with adalimumab (ADA) or placebo (PBO) and the impact of concomitant MTX.

Methods

This was a post hoc analysis of the randomized, double-blind, PBO-controlled ADEPT trial. Subjects were categorized according to time-averaged (TA) disease activity (remission, low, moderate or high) based on Disease Activity Score of 28 joints with CRP [DAS28(CRP)], Disease Activity Index for Psoriatic Arthritis (DAPSA) or Psoriatic Arthritis Disease Activity Score (PASDAS), and achievement of minimal disease activity (MDA) at week 24. Radiographic progression was assessed as change in modified total Sharp score (ΔmTSS) from baseline to week 24. The analyses included inter

SUBMITTER: Landewe R 

PROVIDER: S-EPMC6532443 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature